Anticholinergic Drugs Market: Information by Type (Synthetic
Compounds, Natural, Semi-Synthetic Compounds), Application (Overactive Bladder,
Parkinson’s Disease, Chronic Obstructive Pulmonary Disease, Muscle Spasms,
Irritable Bowel Syndrome), Route of Administration (Oral, Parenteral, Topical),
End User (Hospitals and Pharmacies) and Region - Forecast till 2024
Anticholinergic drugs are
prescribed by doctors for inhibiting the actions of neurotransmitters which are
responsible for involuntary twitching of muscles and other bodily disorders.
They are also used in pre-surgery by anesthesiologists for maintaining normal
body functions. The global anticholinergic drugs market report by Market
Research Future (MRFR) contains numerous trends, opportunities, threats, and
restraints which can prove useful to new investors and entrants.
Market Outlook
The global Anticholinergic
Drugs Market is predicted to exhibit 4.50% CAGR from 2019 to 2024 (forecast
period) to touch a size of USD 7,149.90 million. High prevalence of chronic
diseases is one of the primary drivers of the market. According to the American
Urological Association, nearly 33 million were diagnosed with overactive
bladder (OAB) symptoms. Among them, women had registered a higher percentage
than men. Anticholinergic drugs can block the transmission of acetylcholine, a
chemical which can trigger OAB.
The expanding geriatric populace
and increased inflow of capital in life science research are other main market
drivers. According to the World Health Organization (WHO), the global elderly
populace can double to 50% by 2022. Patients in the U.S. above 65 can exceed by
20% by 2030.
But adverse effects associated
with these drugs can impede market growth.
Segmentation Analysis
The global anticholinergic drugs
market is segmented by type, application, route of administration, and
end-user.
By type, it is segmented into
natural, semi-synthetic compounds, and synthetic compounds. The synthetic
compounds segment is touted to reach a value of USD 4,634.15 million by 2024.
By application, it is segmented
into irritable bowel syndrome, chronic obstructive pulmonary disease,
overactive bladder, muscle spasms, and Parkinson’s disease.
By route of administration, it is
segmented into topical, oral, and parenteral.
By end-user, it is segmented into
pharmacies and hospitals. Hospitals are touted to generate close to USD 4,218.6
million by 2024.
Browse Complete Report :https://www.marketresearchfuture.com/reports/anticholinergic-drugs-market-7895
Regional Analysis
The Middle East & Africa
(MEA), the Americas, Asia Pacific (APAC), and Europe are regions taken into
consideration in the compilation of the global anticholinergic drugs market
report.
The Americas held 39.8% market
share in 2018 and may dominate the global market due to high prevalence of
neurological and kidney disorders. On the other hand, the Europe region is
expected to demonstrate a phenomenal return on earnings during the forecast
period. This can be attributed to the large allocation of healthcare
expenditure for the common public, large geriatric populace, and increasing
cases of kidney diseases. Germany, in particular, held close to 25.8% market
share in Europe.
The APAC region is predicted to
display a robust CAGR during the assessment period due to establishment of
large research and development centers in tandem with new supportive
infrastructure to ensure the constant production. Moreover, setup of production
units in developing countries in the region due to lax tax laws and room for
faster development of anticholinergic drugs can bolster the market volume by a
considerable extent.
Lastly, the MEA region can
exhibit a sluggish growth rate due the large geriatric populace and shortage of
healthcare infrastructure.
Competitive Analysis
Major industry participants in
the global anticholinergic drugs market include GlaxoSmithKline Plc, Teva
Pharmaceutical Industries Ltd, Astellas Pharma Inc., Allergan Plc, Johnson
& Johnson Services Inc., Boehringer Ingelheim International GmbH, Sanofi,
Novartis AG, Mylan N.V., Pfizer Inc., and others. Novel product development in
terms of cost-effective drugs and innovation are strategies being incorporated
by these players.
Industry News
A united research effort headed
by Murdoch Children’s Research Institute and The Royal Children’s Hospital
outlined the high efficacy of three anticholinergic drugs, namely
glycopyrrolate, scopolamine, and benzhexol hydrochloride. These drugs have
shown positive success in reducing drooling in children with learning and
developmental disabilities.
No comments:
Post a Comment